Introduction {#sec1_1}
============

Delirium is a common and severe complication among elderly patients and is associated with increased morbidity and mortality, prolonged hospital stay, increased risk of post-discharge institutionalization and dementia \[[@B1],[@B2]\]. The pathophysiology of delirium is still largely hypothetical. Identifying accurate biomarkers for delirium may shed light on the pathophysiology and may help to improve delirium recognition and care.

Oxidative stress and disturbances in serotonergic and dopaminergic neurotransmission might all be involved in the pathophysiology of delirium and probably act together \[[@B3]\]. Within the central nervous system, tetrahydrobiopterin (BH~4~) functions as an essential cofactor in enzymatic reactions responsible for the production of serotonin and dopamine. In addition, BH~4~ is a cofactor for nitric oxide synthase (NOS) that catalyzes the production of nitric oxide (NO) and citrulline from arginine \[[@B4]\]. If BH~4~ becomes limited, this could impair serotonin and dopamine synthesis. Besides, when BH~4~ is partially deficient, some cellular sources of NOS may generate superoxide (O~2~∙^-^) instead of NO and citrulline \[[@B4],[@B5]\]. In patients with delirium, BH~4~ status has only been investigated after elective cardiac surgery \[[@B6]\].

In order to assess BH~4~ status, we measured amino acid levels and subsequently calculated the phenylalanine/tyrosine (Phe/Tyr) ratio. This ratio is an indicator for the BH~4~ status as it reflects the activity of the enzyme Phe hydroxylase, an enzyme that uses BH~4~ as a cofactor \[[@B4],[@B7]\]. An elevated ratio is suggestive for decreased BH~4~ availability. Furthermore, we determined the ratios of tryptophan (Trp), Phe and Tyr to the other large neutral amino acids (LNAAs). Trp is the precursor of serotonin, while Phe and Tyr are the precursors of dopamine. The LNAAs (Trp, Phe, Tyr, valine, isoleucine and leucine) compete with each other for transport across the blood-brain barrier. Therefore, a decreased Trp/LNAAs ratio is suggestive for a decline in the amount of Trp that enters the brain and consequently for reduced synthesis of serotonin \[[@B8]\]. Moreover, we measured plasma levels of the dopamine metabolite homovanillic acid (HVA), approximately 30% of which is estimated to originate from dopamine neurons in the central nervous system and which is therefore thought to be a reliable indicator for central dopamine activity \[[@B9]\]. Finally, we measured plasma levels of arginine and citrulline to investigate the production of NO by NOS.

The aim of the study was to investigate BH~4~ status, potential disturbances in serotonergic and dopaminergic neurotransmission and the production of NO in patients with and without delirium.

Methods {#sec1_2}
=======

Study Design and Participants {#sec2_1}
-----------------------------

The present study was performed within the Delirium In The Old (DITO) study in which mean levels of neopterin, interleukin-6 and insulin-like growth factor-1 were compared between patients with and without delirium \[[@B10]\]. In the DITO study, a cross-sectional study, we included patients who were admitted to the wards of Internal Medicine and Geriatrics of the Erasmus University Medical Center and the ward of Geriatrics of the Havenziekenhuis, Rotterdam, The Netherlands. All acutely admitted patients aged ≥65 years were eligible to participate. Exclusion criteria were a diagnosis of Lewy body dementia, Parkinson\'s disease, neuroleptic malignant syndrome, tardive dyskinesia, ongoing treatment with antipsychotics or other psychiatric medications except haloperidol and benzodiazepines, aphasia, insufficient understanding of the Dutch language and a Mini-Mental State Examination (MMSE) score \<10 points out of 30. We excluded patients with a MMSE \<10 because it can be quite difficult to distinguish between features of severe dementia and delirium at admission as well as to measure improvement of cognitive function in this group.

Written informed consent was obtained from all participants. In case of delirium or cognitive impairment at the time of admission, informed consent was obtained from a representative of the patient. The Medical Ethics Committee of the Erasmus University Medical Center approved the study protocol.

Procedures {#sec2_2}
----------

All participants were observed daily by the nursing and medical staff and by members of the research team until discharge. To screen for a change in behavior, the 13-item Delirium Observation Screening scale was used during the first 5 days of admission \[[@B11]\]. The diagnosis of delirium was made by a geriatrician, according to the Diagnostic and Statistical Manual of Mental Disorders, 4th edition (DSM-IV) \[[@B12]\], and was based on the psychiatric examination of the patient, the medical and nursing records, including the Delirium Observation Screening scale scores, and information given by the patient\'s closest relative. When the diagnosis of delirium was doubtful, the case was discussed with the geriatric consultation team to gain consensus.

Demographic and clinical data were collected at admission. Age, gender and living situation before admission were documented. Cognitive functioning was assessed in absence of delirium using the MMSE \[[@B13]\]. When it was impossible to score the MMSE during admission because the patient was too ill, cognitive function was discussed with a clinician or assessed with information from the available medical records. When the clinical opinion was that the patient would have a MMSE score ≥10, the patient was not excluded from the study. Severity of comorbidities was scored using the Charlson Comorbidity Index. This index encompasses 19 medical conditions, including dementia, and each condition is weighted with a score of 1-6 by severity \[[@B14]\]. Physical functionality was assessed using the 6-item Katz Activities of Daily Living scale and the Barthel index \[[@B15],[@B16]\]. Instrumental functionality was assessed using the 7-item Older Americans Resource Scale for Instrumental Activities of Daily Living \[[@B15]\]. Frailty was measured with the Identification of Seniors at Risk questionnaire \[[@B17]\]. Blood samples of all patients were collected within 48 h after admission. When a patient developed delirium during the hospital stay, new blood samples were collected within 24 h after the onset of the delirium and were used instead of the first blood samples for the statistical analyses.

Biochemical Measurements {#sec2_3}
------------------------

Non-fasting blood was collected preferably between 8 and 10 a.m. in an 8-ml tube containing ethylene diamine tetraacetic acid. After blood sampling, the tubes were stored at room temperature to prevent changes in the transfer of amino acids between plasma and blood cells \[[@B18]\]. Within 3 h, the blood was centrifuged for 20 min at 2,650 *g* and 20°C. The obtained plasma was stored at −80°C until analysis.

Plasma amino acid levels were determined by high-performance liquid chromatography with automated pre-column derivatization with ortho-phthalaldehyde as previously described \[[@B18]\]. Plasma HVA levels were determined by reversed-phase high-performance liquid chromatography and electrochemical detection, as previously described for the determination of serotonin \[[@B19]\].

Statistical Analysis {#sec2_4}
--------------------

Medians and interquartile ranges were determined for continuous participant characteristics and proportions for categorical characteristics. Biochemical parameters with a skewed distribution were logarithmically transformed (all amino acids, amino acid ratios and HVA). Univariate one-way analysis of variance was used to investigate the association between mean levels of amino acids, amino acid ratios and HVA (dependent variables) and the presence of delirium. Models were adjusted for age, gender and the Charlson Comorbidity Index. Additional analyses were performed for all amino acids, amino acid ratios and HVA after also adding MMSE score to the models. A two-tailed p \<0.05 was defined as statistically significant.

Statistical Package for the Social Sciences, version 21.0 (SPSS Inc., Chicago, Ill., USA) was used to perform the statistical analyses. GraphPad Prism 5.01 for Windows (GraphPad Software, San Diego, Calif., USA) was used to draw all graphs.

Results {#sec1_3}
=======

Participant Characteristics {#sec2_5}
---------------------------

Table [1](#T1){ref-type="table"} presents the baseline characteristics of the 86 participants who were included in the study. Of the 23 patients diagnosed with delirium, 21 were admitted to hospital with delirium and 2 developed delirium during admission.

Analyses of Biochemical Parameters {#sec2_6}
----------------------------------

The mean levels and corresponding 95% confidence intervals (CIs) of the investigated biochemical parameters in patients with and without delirium are presented in tables [2](#T2){ref-type="table"} and [3](#T3){ref-type="table"}. In adjusted models, mean levels of arginine were significantly lower in patients with delirium (34.8 µmol/l, 95% CI 28.8-42.0) than in those without (45.2 µmol/l, 95% CI 40.6-50.5) (p = 0.022) (fig. [1](#F1){ref-type="fig"}). Concerning the amino acid ratios, mean Phe/Tyr ratios were significantly higher in patients with delirium (1.34, 95% CI 1.19-1.51) than in patients without delirium (1.14, 95% CI 1.06-1.22) (p = 0.028) (fig. [1](#F1){ref-type="fig"}). In addition, mean Trp/LNAAs ratios were significantly lower in patients with delirium (4.90, 95% CI 4.19-5.74) than in those without (6.12, 95% CI 5.58-6.71) (p = 0.021) (fig. [1](#F1){ref-type="fig"}). No associations between the other amino acids and ratios and delirium were found, although citrulline (fig. [1](#F1){ref-type="fig"}) and Trp levels were at the border of significance lower in patients with delirium than in those without (p = 0.052 and p = 0.067, respectively).

HVA data were missing for 2 patients (delirium, n = 1 \[not enough plasma\]; no delirium, n = 1 \[measurement failed\]). Mean HVA levels were not statistically significantly different between patients with delirium (123.0 nmol/l, 95% CI 93.3-162.6) and patients without delirium (93.3 nmol/l, 95% CI 79.4-109.4) (p = 0.098).

In the models additionally adjusted for MMSE score, the association between arginine and delirium did not reach statistical significance (delirium: mean 36.0 µmol/l, 95% CI 28.7-45.1 vs. no delirium: mean 44.8 µmol/l, 95% CI 39.8-50.5, p = 0.107). Mean Phe/Tyr ratios remained borderline significantly higher in patients with delirium (1.34, 95% CI 1.16-1.55) than in those without (1.15, 95% CI 1.07-1.24) (p = 0.089) and mean Trp/LNAAs ratios remained borderline significantly lower in patients with delirium (5.00, 95% CI 4.15-6.01) compared to those without (6.15, 95% CI 5.58-6.78) (p = 0.062). Estimates for the other biochemical parameters remained statistically insignificant (data not shown).

Discussion {#sec1_4}
==========

In the present study we found disturbed serotonergic neurotransmission and an increased status of oxidative stress in patients with delirium when compared to patients without delirium.

As far as we are aware, this is the first delirium study investigating BH~4~ status and levels of arginine and citrulline in acutely ill elderly hospitalized patients. In order to assess the BH~4~ status, we measured the Phe/Tyr ratio. In patients with delirium we found an increased ratio, suggesting a deficiency in the essential cofactor BH~4~ for the production of serotonin, dopamine and NO. Decreased BH~4~ availability has already been found in other neuropsychiatric disorders such as Alzheimer\'s disease \[[@B20]\], Parkinson\'s disease \[[@B20]\] and schizophrenia \[[@B21]\]. Our finding is not in agreement with the results of a previous delirium study which showed that levels of BH~4~ and Phe/Tyr ratios did not differ between patients with and without delirium \[[@B6]\]. However, that study included a relatively younger group of patients undergoing elective cardiac surgery.

In the present study, serotonergic neurotransmission was investigated with the Trp/LNAAs ratio and the Phe/Tyr ratio. We found that patients with delirium had a decreased Trp/LNAAs ratio, which might suggest reduced serotonin production in the central nervous system. This hypothesis is strengthened by the finding that patients with delirium had an elevated Phe/Tyr ratio, which might suggest deficiency in the essential cofactor BH~4~ in the production of serotonin. In previous studies, controversial results have been reported. Several studies found a reduced Trp/LNAAs ratio during delirium \[[@B6],[@B8],[@B22],[@B23]\], whereas two studies reported no difference in this ratio between patients with and without delirium \[[@B24],[@B25]\]. The study performed by Flacker and Lipsitz \[[@B24]\] included only patients with mild illnesses not requiring hospitalization. Therefore, the findings may not be generalizable to acutely ill patients who needed medical care in hospital. The study performed by van der Cammen et al. \[[@B25]\] included delirium patients with Alzheimer\'s disease. It might be possible that in those patients a disturbance in cholinergic neurotransmission played a more important role in the development of delirium than disturbances in other pathophysiological pathways \[[@B26]\].

Furthermore, we found no differences in Phe/LNAAs ratios, Tyr/LNAAs ratios and HVA levels between patients with and without delirium, suggesting that dopaminergic neurotransmission is not impaired during delirium. The finding that plasma HVA levels are not significantly increased in patients with delirium compared to patients without delirium is not in agreement with earlier results \[[@B6],[@B25]\]. However, those studies were performed in patients with Alzheimer\'s disease \[[@B25]\] and patients undergoing cardiac surgery \[[@B6]\], and therefore the results may not be generalizable. Ramirez-Bermudez et al. \[[@B27]\] found that cerebrospinal fluid HVA levels correlated with psychotic symptoms of delirium (hallucinations and delusions) in neurological patients. It might also be possible that we did not find an association between the dopaminergic markers and the presence of delirium because we included patients both with and without psychotic features.

In our study, we also found reduced plasma arginine levels and borderline statistically significantly reduced citrulline levels in patients with delirium. Considering the cross-sectional study design, these findings could mean several things. First, it is possible that patients with delirium had a pre-existing arginine deficiency which might have resulted in a reduced production of citrulline by NOS (fig. [2a](#F2){ref-type="fig"}). Second, when BH~4~ is partially deficient, as our results do suggest, some cellular sources of NOS may generate O~2~∙^-^ instead of citrulline and NO from arginine (fig. [2b](#F2){ref-type="fig"}) \[[@B4],[@B5]\], leading to decreased levels of both arginine and citrulline. If this latter scenario is true for delirium, this would also suggest an increased status of oxidative stress, since it favors peroxynitrite formation (fig. [2b](#F2){ref-type="fig"}). If peroxynitrite is not scavenged by antioxidants, it may cause oxidative damage to cellular macromolecules \[[@B20],[@B28]\], which has already been hypothesized to occur in Alzheimer\'s disease \[[@B29]\]. However, both amino acids have been investigated previously by Osse et al. \[[@B6]\] in patients with delirium after cardiac surgery, but they found no differences in arginine and citrulline levels between patients with and without delirium. Since they also reported no difference in BH~4~ status between patients with and without delirium, the results are probable not generalizable to our study.

Limitations and Strengths {#sec2_7}
-------------------------

This study has some limitations. First, our findings were obtained in a relatively small group of patients; therefore, confirmation in a larger population is recommended. Second, it might be speculated that the degree of the patients\' cognitive functioning influenced the mean levels of the biochemical parameters \[[@B20]\]. In this study, we adjusted for the Charlson Comorbidity Index, which includes dementia, and our estimates remained statistically significant. However, for our additional analysis MMSE scores were not available for all patients; therefore, we can neither confirm nor deny that the presence of a comorbid cognitive disturbance, not diagnosed as dementia (yet), was a confounding factor. Third, the timing of blood sampling might be a factor of significance. It is possible that the levels of biochemical markers are dependent on delirium duration and severity or even fluctuate during the day in patients with delirium, just like delirium symptoms. In the present study, blood sampling and delirium occurred on the same day, but there is a possibility that the patients had no delirium symptoms at the moment of blood sampling. This might have influenced our results. Finally, some potential participants were not included in the study and this may have resulted in some selection bias; however, since this was random and occurred in both patients with and without delirium, we think that our results are only minimally influenced by this.

The present study has several strengths. First, the intensive monitoring of clinical symptoms of patients with delirium until discharge and the DSM-IV diagnosis by a geriatrician makes it less likely that we missed delirium or misdiagnosed symptoms. Second, we did not focus on one but on several possible pathways that might lead to delirium as it has been suggested that the pathophysiology is multifactorial.

Conclusion {#sec1_5}
==========

In this study in older, acutely ill hospitalized patients, we found that patients with delirium had higher Phe/Tyr ratios, lower Trp/LNAAs ratios and lower levels of arginine and citrulline than patients without delirium. These findings might suggest that decreased BH~4~ availability, disturbed serotonergic neurotransmission and an increased status of oxidative stress may have played a role in the pathogenesis of delirium in our patient group. Since as far as we know this is the first delirium study investigating BH~4~ status and levels of arginine and citrulline in acutely ill elderly hospitalized patients, confirmation of our results in a larger, comparable population is recommended. Moreover, more research is needed to explore the potential differences in the pathophysiology of delirium in patients with and without cognitive disorders.
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![Schematic presentation of the role of BH~4~ in the formation of citrulline, NO and O~2~∙^-^ by NOS. **a** Situation in which there is sufficient supply of BH~4~ for NOS. **b** Situation in which there is insufficient supply of BH~4~. Some cellular sources of NOS will generate O~2~∙^-^ instead of NO and citrulline. Generation of O~2~∙^-^ and NO together will lead to the formation of peroxynitrite, which may cause oxidative damage.](dee-0005-0450-g02){#F2}

###### 

Characteristics of the study participants

                                                                             No delirium (n = 63)                                 Delirium (n = 23)
  -------------------------------------------------------------------------- ---------------------------------------------------- ----------------------------------------------------
  Male gender                                                                47.6%                                                43.5%
  Age, years                                                                 81.0 (75.0--85.0)                                    87.0 (84.0--88.0)
  MMSE score[^a^](#T1F1){ref-type="table-fn"}                                25.5 (22.0--28.0)[^b^](#T1F2){ref-type="table-fn"}   20.0 (18.0--25.0)[^c^](#T1F3){ref-type="table-fn"}
  Living situation                                                                                                                
   Home                                                                      47.6%                                                26.1%
   Home care                                                                 31.7%                                                30.4%
   Residential home                                                          7.9%                                                 17.4%
   Nursing home                                                              3.2%                                                 13.0%
   Missing data                                                              9.5%                                                 13.0%
  Katz Activities of Daily Living score[^d^](#T1F4){ref-type="table-fn"}     0.0 (0.0--3.0)                                       2.0 (1.0--11.0)
  OARS-IADL score[^e^](#T1F5){ref-type="table-fn"}                           5.0 (0.0--10.0)                                      9.5 (3.5--14.0)
  Barthel index[^f^](#T1F6){ref-type="table-fn"}                             18.0 (13.0--20.0)                                    16.0 (9.5--19.0)
  Identification of Seniors at Risk score[^g^](#T1F7){ref-type="table-fn"}   4.0 (2.0--6.0)                                       6.0 (4.8--7.0)
  Charlson Comorbidity Index[^h^](#T1F8){ref-type="table-fn"}                1.0 (1.0--2.0)                                       2.0 (1.0--3.0)

Values are expressed as medians (interquartile ranges) or percentages.

OARS-IADL = Older Americans Resource Scale for Instrumental Activities of Daily Living.

Range 0 (severe cognitive impairment) to 30 (no cognitive impairment).

Three values missing.

Four values missing.

Range 0 (no disability) to 12 (severe disability).

Range 0 (no disability) to 14 (severe disability).

Range 0 (severe disability) to 20 (no disability).

Scores ≥2 indicate a high risk of functional decline.

Range 0--37 (severe burden of comorbidities).

###### 

Mean levels of amino acids

                          No delirium (n = 63)   Delirium (n = 23)      p value
  ----------------------- ---------------------- ---------------------- ---------
  Glutamic acid, μmol/l   46.2 (40.9--52.2)      41.3 (33.5--50.9)      0.368
  Serine, µmol/l          84.5 (78.7--90.8)      81.3 (71.9--91.8)      0.596
  Glycine, μmol/l         194.5 (179.5--210.9)   187.1 (162.6--214.8)   0.633
  Citrulline, μmol/l      29.4 (26.1--33.3)      23.0 (18.6--28.4)      0.052
  Arginine, μmol/l        45.2 (40.6--50.5)      34.8 (28.8--42.0)      0.022
  Alanine, μmol/1         329.6 (297.1--364.8)   337.3 (283.1--402.7)   0.814
  Taurine, μmol/1         41.3 (37.4--45.5)      38.5 (32.6--45.6)      0.496
  Tyr, µmol/1             58.6 (54.0--63.7)      55.6 (48.2--64.1)      0.529
  Valine, µmol/1          212.8 (198.2--228.0)   214.8 (190.5--241.5)   0.898
  Methionine, μmol/1      22.4 (20.8--24.3)      23.3 (20.4--26.5)      0.651
  Trp, µmol/1             32.1 (28.8--35.7)      26.2 (21.8--31.5)      0.067
  Phe, μmol/1             66.7 (62.2--71.4)      74.5 (66.2--83.8)      0.122
  Isoleucine, µmol/1      59.6 (55.0--64.6)      57.7 (50.2--66.2)      0.690
  Leucine, μmol/1         120.5 (111.4--130.6)   123.3 (107.6--141.3)   0.783
  Ornithine, μmol/1       78.0 (71.0--85.5)      67.6 (57.5--79.4)      0.146

Values are expressed as means (95% CIs) and are the back-transformed log~10~ values. Models are adjusted for age, gender and Charlson Comorbidity Index.

###### 

Mean levels of amino acid ratios and HVA

                           No delirium (n = 63)                                  Delirium (n = 23)                                      p value
  ------------------------ ----------------------------------------------------- ------------------------------------------------------ ---------
  Phe/Tyr ratio            1.14 (1.06--1.22)                                     1.34 (1.19--1.51)                                      0.028
  Trp/LNAAs ratio (×100)   6.12 (5.58--6.71)                                     4.90 (4.19--5.74)                                      0.021
  Tyr/LNAAs ratio (×100)   11.8 (11.0--12.7)                                     11.0 (9.7--12.4)                                       0.342
  Phe/LNAAs ratio (×100)   13.6 (12.7--14.7)                                     15.3 (13.6--17.3)                                      0.122
  HVA, nmol/l              93.3 (79.4--109.4)[^a^](#T3F1){ref-type="table-fn"}   123.0 (93.3--162.6)[^a^](#T3F1){ref-type="table-fn"}   0.098

Values are expressed as means (95% CIs) and are the back-transformed log~10~ values. Models are adjusted for age, gender and Charlson Comorbidity Index.

One value missing.
